Compare HRMY & RBCAA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | HRMY | RBCAA |
|---|---|---|
| Founded | 2017 | 1974 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Major Banks |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.6B | 1.4B |
| IPO Year | 2020 | 1998 |
| Metric | HRMY | RBCAA |
|---|---|---|
| Price | $31.05 | $76.30 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 9 | 1 |
| Target Price | ★ $44.11 | N/A |
| AVG Volume (30 Days) | ★ 793.3K | 57.3K |
| Earning Date | 05-07-2026 | 04-23-2026 |
| Dividend Yield | N/A | ★ 2.41% |
| EPS Growth | ★ 7.97 | N/A |
| EPS | ★ 2.71 | 0.77 |
| Revenue | ★ $868,453,000.00 | $417,495,000.00 |
| Revenue This Year | $19.75 | $3.93 |
| Revenue Next Year | $12.88 | N/A |
| P/E Ratio | ★ $12.04 | $99.92 |
| Revenue Growth | ★ 21.51 | 8.50 |
| 52 Week Low | $25.52 | $63.97 |
| 52 Week High | $40.87 | $78.00 |
| Indicator | HRMY | RBCAA |
|---|---|---|
| Relative Strength Index (RSI) | 51.87 | 58.87 |
| Support Level | $25.92 | $67.02 |
| Resistance Level | $30.96 | N/A |
| Average True Range (ATR) | 1.47 | 2.03 |
| MACD | 0.07 | 0.07 |
| Stochastic Oscillator | 35.36 | 84.31 |
Harmony Biosciences Holdings Inc is a commercial-stage pharmaceutical company focused on developing and commercializing therapies for patients living with rare neurological diseases who have unmet medical needs. The company has one reportable segment: rare neurological diseases. Its product WAKIX (pitolisant) is a molecule with a novel mechanism of action specifically designed to increase histamine signaling in the brain by binding to H3 receptors and is used for the treatment of cataplexy in adult patients with narcolepsy. The other drug candidates in its pipeline are Pitolisant, HBS-102 (MCHR1 antagonist), BP1.15205 (orexin-2 receptor agonist), ZYN002 (cannabidiol gel), EPX-100 (clemizole hydrochloride), and EPX-200 (lorcaserin), among others.
Republic Bancorp Inc operates as a financial institution that provides both traditional and non-traditional banking products through five reportable segments. It has traditional banking, which generates the majority of revenue, Warehouse Lending, Tax Refund Solutions (TRS), Republic Payment Solutions segment, and Republic Credit Solutions (RCS) business segments. The business activities of these segments include retail mortgage and commercial lending, construction and land development lending, internet lending, correspondent and indirect lending, and also private banking, treasury management services, internet, and mobile banking, bank acquisitions, short-term revolving credit facilities, fixed-term residential real estate loans, and receipt and payment of federal.